Not every Medicare pullback is about doctors and hospitals. Molina Healthcare is walking away from the standalone Medicare drug-plan business for 2027, a move aimed squarely at prescription coverage rather than medical care. Its enrollees in that stand-alone Part D plan will have to pick a new drug plan during this fall’s open enrollment or risk being left without prescription coverage, and possibly a lasting penalty, when the calendar turns.
What a standalone Part D plan does that a medical plan doesn’t
A standalone prescription drug plan, known as a PDP, is bought separately from a person’s other Medicare coverage. It is the drug benefit that people on Original Medicare add to cover their pharmacy costs, and it is distinct from a Medicare Advantage plan that bundles medical and drug coverage together. Molina’s exit hits that specific product line, the drug-only plan, not a full medical plan.
That distinction shapes what affected members need to replace. Someone losing a Molina PDP is not necessarily losing medical coverage; the piece that disappears is the drug plan attached to it. The replacement can be another standalone Part D plan for those staying on Original Medicare, or a Medicare Advantage plan that includes drug coverage for those willing to switch how their medical care is delivered.
Free retirement updates: Enrollment and claim windows come and go, and missing one can cost real money. The free Retirement Shield newsletter keeps readers ahead of the deadlines that matter. Sign up free.
The late-enrollment penalty that makes a gap expensive
The reason a PDP exit is more than an inconvenience is a penalty that follows a person for as long as they stay on Medicare. Anyone who goes without creditable prescription coverage for 63 days or more, and later signs up for a drug plan, can be charged a late-enrollment penalty that is added permanently to the monthly premium. The longer the gap, the larger the surcharge, and it does not go away once it attaches.
That is why a discontinued drug plan cannot simply be ignored. A Molina member who assumes coverage will roll over, and lets the deadline slip, risks both an interruption in filling prescriptions and a lifetime add-on to future premiums. Choosing a replacement plan before the old one lapses is what keeps that penalty from ever starting.
The surcharge is also larger than many expect, because it compounds with time. Medicare calculates the penalty as roughly one percent of the national base drug-plan premium for every month a person went without creditable coverage, then adds that amount to the premium and recalculates it each year as the base premium changes. A gap measured in months rather than weeks can translate into a permanent monthly cost that grows over a retirement, which is what makes a lapse after a plan exit so consequential.
Why standalone drug plans are getting squeezed out
Molina is not the only carrier retreating from the drug-plan aisle. Standalone PDPs have become a thin-margin business since the Inflation Reduction Act redesigned how Part D works, capping out-of-pocket drug spending and shifting more of the catastrophic-coverage cost onto insurers. Those changes improved the deal for many patients but squeezed the profitability of plans that sell drug coverage on its own, prompting several insurers to reconsider whether the product is worth offering. Molina is among the carriers stepping back as that math shifts.
The consequence for the market is fewer standalone choices in some regions and more pressure on the plans that remain. For a member who wants to stay on Original Medicare plus a drug plan, rather than move into a bundled Medicare Advantage plan, the field of standalone options may be smaller in 2027 than it was the year before.
The fall window that has to be used
The path to replacement runs through the same calendar that governs every Medicare change. The Annual Enrollment Period from October 15 through December 7 is the main window to select a new Part D or Medicare Advantage drug plan for coverage that starts January 1. A member whose plan is being discontinued should receive a non-renewal notice this fall confirming the plan will not return, which is the cue to start comparing.
Comparing plans on drug coverage means looking past the premium to the formulary, the list of drugs a plan covers, and the pharmacy network. A cheaper plan that does not cover a specific medication, or that treats a member’s regular pharmacy as out of network, can cost more in the end than a plan with a higher premium and better coverage for the drugs actually taken.
Lower-income enrollees have an extra layer of protection worth knowing about. People who receive the Part D low-income subsidy, often called Extra Help, are generally reassigned by Medicare to another qualifying drug plan at no premium when their current plan leaves the market, so they are not left uncovered by default. Even so, the plan Medicare picks may not be the strongest match on formulary or pharmacy, so an affected member who receives Extra Help still benefits from comparing the assigned plan against the alternatives during open enrollment rather than accepting the automatic placement without a look.
Why the details firm up only in the fall
Molina’s decision to leave the standalone market is set, but the granular picture, which replacement plans will be available in a given area and at what price, does not become final until 2027 plan data posts on the Medicare Plan Finder in the fall, ahead of the October 15 start. Until then, the exit is confirmed while the alternatives remain preliminary. The fixed point a member can act on now is the deadline itself: a drug plan that ends December 31 needs a replacement chosen during open enrollment, both to keep prescriptions flowing and to avoid a penalty that never expires.
This article was produced with the assistance of artificial intelligence and reviewed by The Financial Wire editorial team.
More Financial Reading
- How many CDs can you park at 1 bank? FDIC rules you must know
- What really happens to your joint savings account when you die?
